Tevogen Bio
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Tevogen Bio
- Ryan Saadi, Chairman of the Board and Chief Executive Officer
- Lindee Goh, Director
- Curtis Patton, Director
Popular executive movements at Tevogen Bio
- Tapan Shah has joined the company as Head of Investor Relations and Corporate Development (posted on April 5 2024).
- Mittul Mehta has joined the company as Chief Information Officer and Head of Tevogen.ai (posted on October 24 2023).
Create your alert
to follow the executive moves at Tevogen Bio.
Biotechnology
Tevogen Bio has 2,290 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
- Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).
Popular contacts in Biotechnology
News
Press releases by Tevogen Bio
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Reports Series A-1 Preferred Stock Investment
- Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
- Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
- Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus
- Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
- Tevogen Bio Announces $8 Million Equity Investment
- Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
- View more press releases Close
Social media about Tevogen Bio
- Tevogen Bio on Wikipedia, Google News & Yahoo Finance
- Tevogen Bio on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ryan Saadi 
